Literature DB >> 6193515

Ganglioside GM2 as a human tumor antigen (OFA-I-1).

T Tai, J C Paulson, L D Cahan, R F Irie.   

Abstract

A monospecific antibody produced in vitro by a B-lymphoblastoid cell line transformed with Epstein-Barr virus has been shown to recognize a membrane antigen (OFA-I-1) on human tumors and fetal brain. This study identifies the chemical nature of OFA-I-1. The glycolipid fraction of antigen-rich spent medium of an OFA-I-1-positive melanoma cell line, M14, was extracted by chloroform/methanol/water, 4:8:3 (vol/vol), and was separated into fractions of neutral glycolipids and gangliosides by DEAE-Sephadex followed by base treatment and Bio-sil A column elution. OFA-I-1 antigens were found exclusively in the ganglioside fraction when assayed with monospecific anti-OFA-I-1 by an immune adherence inhibition test. The results obtained from thin-layer chromatography of the antigenic M14 ganglioside and sequential glycosidase digestion suggested that the antigen was a ganglioside GM2, GalNAc beta 1 leads to 4(NeuAc alpha 2 leads to 3)Gal beta 1 leads to 4Glc leads to Cer. These results were further supported by testing various authentic gangliosides and neutral glycolipids for OFA-I-1 antigenicity. Only GM2 showed positive reactivity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193515      PMCID: PMC384262          DOI: 10.1073/pnas.80.17.5392

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  The thiobarbituric acid assay of sialic acids.

Authors:  L WARREN
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

Review 2.  THE GANGLIOSIDES.

Authors:  L SVENNERHOLM
Journal:  J Lipid Res       Date:  1964-04       Impact factor: 5.922

3.  The quantitative estimation of cerebrosides in nervous tissue.

Authors:  L SVENNERHOLM
Journal:  J Neurochem       Date:  1956-05       Impact factor: 5.372

4.  The purification and properties of beta-galactosidase from bovine testes.

Authors:  J J Distler; G W Jourdian
Journal:  J Biol Chem       Date:  1973-10-10       Impact factor: 5.157

5.  The pattern of mammalian brain gangliosides. 3. Regional and developmental differences.

Authors:  K Suzaki
Journal:  J Neurochem       Date:  1965-12       Impact factor: 5.372

6.  Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

Authors:  K Irie; R F Irie; D L Morton
Journal:  Science       Date:  1974-11-01       Impact factor: 47.728

7.  Isolation and characterization of human liver hematoside.

Authors:  T N Seyfried; S Ando; R K Yu
Journal:  J Lipid Res       Date:  1978-07       Impact factor: 5.922

8.  Quantitative isolation of total glycosphingolipids from animal cells.

Authors:  T Saito; S I Hakomori
Journal:  J Lipid Res       Date:  1971-03       Impact factor: 5.922

9.  Enzymatic properties of beta-D-galactoside alpha2 leads to 6 sialytransferase from bovine colostrum.

Authors:  J C Paulson; J I Rearick; R L Hill
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

10.  A membrane antigen common to human cancer and fetal brain tissues.

Authors:  R F Irie; K Irie; D L Morton
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

View more
  27 in total

Review 1.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.

Authors:  D R Vlock; J M Kirkwood
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

4.  Cell-surface antigens of melanoma recognized by human monoclonal antibodies.

Authors:  H Yamaguchi; K Furukawa; S R Fortunato; P O Livingston; K O Lloyd; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 5.  Immunotherapy with monoclonal antibodies in metastatic melanoma.

Authors:  T A Steffens; D F Bajorin; A N Houghton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

6.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Cellular immuno-PCR. Detection of a carbohydrate tumor marker.

Authors:  Z Zhang; R F Irie; D D Chi; D S Hoon
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

8.  Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Authors:  P O Livingston; E J Natoli; M J Calves; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

Review 9.  GM2 ganglioside and pyramidal neuron dendritogenesis.

Authors:  S U Walkley; D A Siegel; K Dobrenis
Journal:  Neurochem Res       Date:  1995-11       Impact factor: 3.996

10.  Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

Authors:  P Hersey; A Edwards; G D'Alessandro; M MacDonald
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.